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Eph-B receptor activation.
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Metabolic pathways, once seen as a mere conse-
quence of cell states, have emerged as active players
in dictating different cellular events such as prolifer-
ation, self-renewal, and differentiation. Several
studies have reported a role for folate-dependent
one-carbon (1C) metabolism in stem cells; however,
its exact mode of action and how it interacts with
other cues are largely unknown. Here, we report a
link between the Eph:ephrin cell-cell communication
pathway and 1C metabolism in controlling neural
stem cell differentiation. Transcriptional and func-
tional analyses following ephrin stimulation revealed
alterations in folate metabolism-related genes and
enzymatic activity. In vitro and in vivo data indicate
that Eph-B forward signaling alters the methylation
state of H3K4 by regulating 1C metabolism and
locks neural stem cell in a differentiation-ready state.
Our study highlights a functional link between cell-
cell communication, metabolism, and epigenomic
remodeling in the control of stem cell self-renewal.
INTRODUCTION
A distinctive feature of stem cells (SCs) is their dual capacity for
self-renewal and multipotent differentiation. Recent evidence
has revealed that, in addition to signaling via growth factors
and the extracellular matrix, metabolic pathways contribute to
the balance between self-renewal and differentiation of SCs.
Indeed, a switch inmetabolic pathways correlates with SCdiffer-
entiation through coordination with signaling and genetic/epige-
netic regulation (Folmes et al., 2012b; Zhang et al., 2012). In the
developing brain, a tight balance between self-renewal and dif-
ferentiation of neural SCs (NSCs) is important to ensure that
correct numbers of neural cells are generated (Go¨tz et al.,
2016). While several studies have highlighted an important role
for glycolysis, lipogenesis, and mitochondrial activity in neuro-
genesis (Knobloch and Jessberger, 2017), the one-carbon (1C)
pathway has comparatively received less attention.2864 Cell Reports 23, 2864–2873, June 5, 2018 ª 2018 The Author(s
This is an open access article under the CC BY-NC-ND license (http://1C metabolism is a universal metabolic pathway that couples
purine synthesis (required for DNA replication and cell prolifera-
tion) and methyl carrier S-adenosylmethionine (SAM) synthesis,
which is required for methylation reactions (Ducker and Rabino-
witz, 2017). It thus affects epigenetic programs viamethylation of
histone and DNA. Folate, an essential co-factor in the 1C meta-
bolism, is best known as a vitamin that prevents neural tube de-
fects during fetal development (Schorah et al., 1980), and whose
deficiency contributes to severe neurodevelopmental and
neurological disorders (Serrano et al., 2012). Previous studies
have highlighted the role of folate in NSC self-renewal and differ-
entiation. For instance, folate deficiency inhibits the proliferation
of adult hippocampal NSCs in vivo and induces NSC apoptosis
in vitro (Kruman et al., 2005; Zhang et al., 2008). Conversely,
NSCs respond to folate with increased proliferation and neuronal
differentiation (Liu et al., 2013; Luo et al., 2013). These reports
point out the role of 1C metabolism in NSC regulation; however,
whether and how it interacts with other regulatory mechanisms
that control neurogenesis remain unknown.
Here, we report a link between the Eph:ephrin cell-cell
communication pathway and 1C metabolism. Eph receptors,
the largest family of receptor tyrosine kinases and their ligands,
the ephrins, participate in a wide spectrum of developmental
processes and play a role in both embryonic and adult neurogen-
esis (Laussu et al., 2014). Specifically, activation of Eph-B
signaling has been shown to promote differentiation of adult
NSCs (Ashton et al., 2012; Ottone et al., 2014). However, even
though downstream effectors of Eph receptors, such as cyto-
plasmic kinases and phosphatases are well studied in the
context of tissue morphogenesis or axon guidance (Kania and
Klein, 2016), the molecular mechanisms underlying their effect
on neurogenesis remain poorly understood.
We used in vitro and in vivo analyses of embryonic NSCs to
identify the molecular mechanisms controlling self-renewal and
differentiation downstream of Eph-B receptors. Combination of
transcriptional, enzymatic, and genetic analyses revealed a link
between Eph-B signaling and dihydrofolate reductase (DHFR),
a key enzyme of the 1C folate pathway. We show that ephrinB1
stimulation inhibits DHFR expression, and this leads to increased
NSC differentiation in vitro and in the developing neocortex.
Furthermore, we present evidence that Eph-B forward signaling
through alterations in 1Cmetabolismmodifies H3K4methylation).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Eph-B Forward Signaling Controls DHFR Expression via AKT
(A) Gene ontology enrichment analysis of differentially expressed genes following eB1-Fc treatment.
(B) Average signal intensity of microarray data at 2 and 6 hr of treatment for genes in the 1C folate metabolic pathway (n = 3 biological replicates).
(C) One-carbon folate pathway. Genes whose expression changes upon eB1-Fc treatment are shown in red.
(D) qRT-PCR analysis of NSCs treated for 6 hr with eB1-Fc (n = 3–7 biological replicates).
(E) NSCs were treated as in (B) for the indicated time. Samples were analyzed by western blot.
(F) DHFR activity in NSC lysates treated with either with eB1-Fc or MTX for the indicated times (n = 3–5 replicates).
(G) NSCs were treated with eB1-Fc for 30 min and 72 hr in presence or absence of the AKT inhibitor MK-2206 and analyzed by western blot.
(H) NSCs were transfected with E2F1 or YY1 small interfering RNA (siRNA), treated with eB1-Fc for 72 hr, and analyzed by western blot.
(I) NSCs were treated with eB1-Fc for 72 hr, and E2F1 ChIP was performed using two primer pairs specific for the Dhfr promoter (n = 3–4 replicates).
(legend continued on next page)
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on progenitor genes. Finally, we show that these epigenetic
changes are inherited and maintained in the long term and that
NSCs are locked in a differentiation-ready state.
RESULTS
Eph-B Forward Signaling Inhibits DHFR Expression
To identify downstream effectors of Eph-B forward signaling in
NSCs, we performed transcriptional analyses of NSCs stimu-
lated with ephrin-B1 recombinant protein (eB1-Fc) for 2 and
6 hr. eB1-Fc stimulation led to transient phosphorylation of
Eph-B receptors (Figure S1A) and to differential expression of
about 400 genes (Figures S1B and S1C). Gene ontology annota-
tion revealed enrichment in genes involved in regulation of gene
expression, cellular component organization, and metabolic and
cellular processes (Figure 1A). In particular, expression of several
genes from the 1C folate pathway was decreased (Figures 1B
and 1C). Some of these target genes were validated by qRT-
PCR, and among them, Dhfr was significantly downregulated
following eB1-Fc treatment (Figure 1D). This decrease in Dhfr
mRNA correlated with a detectable decrease of DHFR protein
levels 72 hr post-eB1-Fc treatment (Figure 1E). DHFR is a key
enzyme in the 1C metabolic pathway whose activity is inhibited
by methotrexate (MTX), an anti-folate compound (Goldin et al.,
1955). To evaluate the impact of Eph signaling on DHFR activity,
we measured its enzymatic activity in NSCs following eB1-Fc
treatment and MTX treatment. eB1-Fc treatment inhibited
DHFR activity in NSCs as efficiently as MTX, but with slower
kinetics (Figure 1F).
Intracellular effectors downstream of Eph-B have been
described in several contexts (Kania and Klein, 2016); however,
how Eph signaling may regulate transcription has yet to be fully
understood. One potential candidate effector is AKT, which acts
as a hub controlling the activity of a number of transcription fac-
tors (TFs) (Manning and Cantley, 2007). Indeed, upon eB1-Fc
treatment, AKT is phosphorylated with similar kinetics to those
observed for Eph-B (Figure S1D) and AKT inhibition prevented
the decrease in DHFR protein levels 72 hr post-eB1-Fc treatment
(Figures 1G and S1E). One strong candidate TF downstream of
Eph-AKT signaling is E2F1, which is known to control Dhfr
expression (Slansky et al., 1993). Indeed, knockdown of E2F1
expression, but not YY1, in NSCs led to a decrease in DHFR pro-
tein levels (Figure 1H) and E2F1 binding to the Dhfr promoter is
decreased upon Eph signaling activation (Figure 1I).
We generated Efnb1/Efnb2 double-knockout (dKO) embryos
to confirm the link between Eph/AKT and DHFR expression
genetically, and analyzed neocortical tissue at embryonic day
13.5 (E13.5), a developmental stage at which the neocortex is
mostly composed of neural progenitors. As expected, western-
blot analyses show that phosphorylation of Eph-B receptors
and AKT is decreased in dKO embryos (Figure S1F). Importantly,
inactivation of Eph-B signaling in dKO embryos correlated with
increased DHFR protein levels compared to wild-type embryos(J) Western blot analysis of E13.5 wild-type (WT) and Efnb1/; Efnb2lox/lox; nesti
Experiments were performed on at least three different cultures, except (B) (n = 3–7
(J). Statistical analysis was performed using Mann-Whitney test (D and I) and one
mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.005).
2866 Cell Reports 23, 2864–2873, June 5, 2018(Figure 1J). In addition, data mining of a single-cell RNA-
sequencing (RNA-seq) dataset (Okamoto et al., 2016) revealed
an inverse correlation between Dhfr and EphB2 expression in
mouse embryonic cortical progenitors (Figure S1G). Altogether,
our data show that activation of Eph-B signaling inhibits DHFR
expression via AKT and E2F1.
Eph-B Forward Signaling Promotes NSC Differentiation
by Inhibiting DHFR
To test whether DHFR inhibition is required for Eph-induced
NSC differentiation, we treated NSCs with a single dose of
eB1-Fc with or without folinic acid (FNA), which replenishes tet-
rahydrofolic acid pools depleted by DHFR inhibition (van Ede
et al., 2001). eB1-Fc treatment led to a decreased number of
secondary spheres, which is a hallmark of impaired self-
renewal, and this was rescued by FNA supplementation (Fig-
ure 2A), indicating that this phenotype is due to inhibition of
DHFR. Inhibition of DHFR by knocking down of E2F1 (Figure 2B)
or by MTX treatment (Figure S2A) also led to a decrease in the
number of secondary spheres. We then quantified SOX2+ self-
renewing cells by fluorescence-activated cell sorting (FACS)
and immunofluorescence (IF) analyses. While at 72 hr eB1-Fc
treatment had no effect on the number of SOX2+ cells (Fig-
ure S2B), at 7 days, eB1-Fc treatment led to a decrease in
SOX2+ cells, which was rescued by FNA treatment (Figures
2C and 2D). Inhibition of DHFR activity by MTX and E2F1
knockdown also led to a reduction in SOX2+ cells (Figures
S2C–S2E). Similar changes were observed for Nestin+ cells
(Figures 2D and S2D). The reduction in the pool of self-renew-
ing cells is not due to a decrease in their proliferation rate (Fig-
ure 2E), or to increased apoptosis (Figures 2F–2I). Instead,
while eB1-Fc treatment had no effect on the fraction of cells ex-
pressing differentiated markers (O4, GFAP, bIII-tubulin) at 72 hr
(Figure 2J), we observed an expansion of this fraction 7 days
post-treatment (Figures 2K, S2F, and S2G). While FNA supple-
mentation alone had no effect on NSC differentiation, it pre-
vented differentiation following eB1-Fc treatment (Figure 2K).
In conclusion, activation of Eph-B signaling leads to a decrease
in DHFR expression and activity, which depletes the progenitor
pool and promotes differentiation.
To evaluate the importance of the Eph-B/DHFR axis in the
control of NSC differentiation in vivo, we injected eB1-Fc or
eB1-Fc with FNA into the ventricles of E13.5 embryos in utero
and analyzed the progenitor and neuronal fractions at E16.5.
eB1-Fc treatment decreased SOX2+ cells number in the ventric-
ular zone of the neocortex (Figures 2L and 2M), which correlated
with increased number of neurons in the cortical plate (Figures
2N and 2O), and this was rescued by FNA supplementation (Fig-
ures 2L–2O). FNA supplementation had no significant effect
alone (Figures S2H and S2I). These in vivo results corroborate
in vitro data and strongly support the causal relationship
between Eph-B forward signaling, DHFR inhibition, and NSC
differentiation.n-Cre (eB1/eB2 dKO) embryonic neocortex (n = 4 embryos of each genotype).
replicates).Western blots are representative of at least three replicates except
-way ANOVA test followed by the Bonferroni method (F). Data are reported as
Figure 2. Eph-B Forward Signaling Promotes NSC Differentiation by Inhibiting DHFR
(A) Neurospheres were dissociated and incubated for 7 days with either eB1-Fc or eB1-Fc supplemented with FNA as indicated. Neurospheres were then
dissociated and cultured under stem culture conditions (102 cells/mL) for 1 week, and the number of spheres were counted. Sphere-forming unit (SFU) is
calculated according to the following formula: SFU = (number of spheres counted/number of input cells)*100 (n = 3 biological replicates).
(B) NSCs were transfected with E2F1 or YY1 siRNA and SFU was quantified (n = 3 biological replicates).
(C) Quantification by FACS of NSCs treated as in (A) and stained with SOX2 antibody (n = 3–5 replicates; **p < 0.01).
(D) Representative immunofluoresence images of neurospheres treated with eB1-Fc for 7 days and stained with SOX2 (red) and Draq5 (blue).
(E) Quantification of cell numbers after 4, 8, 12, and 16 days of treatment with eB1-Fc (n = 3 biological replicates).
(F) Representative immunofluoresence images of neurospheres treatedwith eB1-Fc for 7 days and stained with pS10H3 (H3P) antibody (green) and DraQ5 (blue).
(G) Quantification of H3P-positive cells from (F) (n = 4 replicates).
(H) Representative immunofluoresence images of neurospheres treated as in (F) and stained with cleaved caspase 3 (CC3) antibody (red) and DraQ5 (blue).
(I) Quantification of CC3-positive cells from (H).
(legend continued on next page)
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Figure 3. Inhibition of DHFR via Eph-B For-
ward Signaling Alters Epigenetic Marks in
NSCs
(A) NSCswere treated for 72 hr withMTX or eB1-Fc
and analyzed by western blot.
(B)Western blot analysis of NSCs treatedwithMTX
or eB1-Fc for 72 hr and supplemented with FNA as
indicated.
(C) NSCs were transfected with HA-tagged DHFR
L1, treated with eB1-Fc for 72 hr, and analyzed by
western blot using the indicated antibodies.
(D–I) NSCs were treated with eB1-Fc for 72 hr, and
qRT-PCR analysis of the promoter region of
selected genes after H3K4me3 ChIP was per-
formed: Sox2 (D), Nes (E), GFAP (F), Olig2 (G), Dcx
(H), and Ccdc (I). The figure shows the H3K4me3
methylation profile as extracted from Albert et al.
(2017); the location of primer pairs is relative to
published H3K4me3 ChIP-seq data.
(J) NSCswere treated for 72 hr with oligomycin and
analyzed by western blot.
(K) NSCs were treated for 72 hr with oligomycin.
The graph shows qRT-PCR analysis of the
promoter region of selected genes following
H3K4me3 ChIP.
Experiments were performed on three different
cultures (n = 3–5 replicates). Western blots are
representative of at least three replicates. Statis-
tical analysis was performed using paired t test
(D–I and K). Data are reported as mean ± SEM
(*p < 0.05).Inhibition of DHFR via Eph-B Forward Signaling Alters
Epigenetic Marks in NSCs
DHFR is a key enzyme in the 1C folate pathway that affects both
cell proliferation and methylation reactions (Figure 1C). Since we
did not detect changes in NSC proliferation upon eB1-Fc treat-
ment (Figures 2E and 2F), we explored the possibility that activa-
tion of Eph signaling may impact methylation reactions. It was
recently shown that 1C folate pathway controls histone-3(J) Quantification by FACS of eB1-Fc-treated NSCs for 72 hr and stained with TUJ1, O4, and GFAP antibodies
replicates).
(K) Quantification by FACS analysis of NSCs treated with eB1-Fc, FNA alone, or eB1-Fc/FNA for 7 days and
graph represents pooled data (n = 4 replicates).
(L) Representative confocal images of E16.5 coronal sections of embryonic neocortex 72 hr after in utero inje
SOX2 (red) and DAPI (gray).
(M) Quantification of SOX2+ cells from (L) (n = 3–4 embryos).
(N) Representative confocal images of E16.5 coronal sections of embryonic neocortex 72 hr after in utero inje
TBR1 (red), SATB2 (green), and DraQ5 (gray).
(O) Quantification of TBR1+/SATB2+ neurons from (N) (n = 3–4 embryos).
Abbreviations: h, hours; d, days. Scale bars represent 100 mm. Experiments were performed on at least t
replicates). Statistical analysis was performed using one-way ANOVA test followed by the Bonferroni method (
LSD test (C), multiple t test using the Holm-Sidak method (E) and Mann-Whitney test (G, I, and J). Data are
2868 Cell Reports 23, 2864–2873, June 5, 2018methylation (Garcia et al., 2016; Mentch
et al., 2015; Shyh-Chang et al., 2013),
which is required for the maintenance of
defined cellular states (Benayoun et al.,
2014). We thus assessed several methyl-
ation marks on histone-3 following eB1-
Fc or MTX treatments. At 72 hr, prior toany detectable differentiation, eB1-Fc and MTX treatments led
to a significant decrease in H3K4me3 levels (Figure 3A), which
correlated temporally with the decrease in DHFR expression
and activity (Figure S3A). This decrease in H3K4me3 was due
to altered 1C folate metabolism since it was rescued by FNA
supplementation in both eB1-Fc andMTX treatments (Figure 3B).
Furthermore, exogenous expression of DHFR (the L1 variant that
is not detected by the anti-DHFR antibody) prevented the. The graph represents pooled data (n = 3 biological
stained with TUJ1, O4, and GFAP antibodies. The
ction of eB1-Fc or eB1-Fc and FNA and stained for
ction of eB1-Fc or eB1-Fc and FNA and stained for
hree different cultures, except (H) and (I) (n = 3–5
A,M, andO), Holm-Sidak’s (A, B, and K), or Fisher’s
reported as mean ± SEM (*p < 0.05).
Figure 4. Long-Term Inheritance of the Pro-differentiative Program Induced by Eph Signaling
(A) Graphical presentation of the in vitro experimental design. First-generation NSCs were treated and cultured for 7 days. Neurospheres were then dissociated
and cultured without treatment under stem cell culture conditions. Second-generation NSCs were assessed at 10 days with ChIP and DHFR activity, at 14 days
with FACS and IF, and at 21 days with SFU.
(B) DHFR activity was measured in second-generation NSCs as described in (A).
(C) SFU was quantified on second-generation NSCs as described in (A).
(D) First-generation NSCs were treated as indicated, and second-generation NSCs were immunostained with SOX2 and analyzed by FACS.
(E) First-generation NSCs were treated as indicated, and second-generation NSCs were immunostained with TUJ1, O4, and GFAP antibodies and analyzed by
FACS. The graph represents pooled data.
(F) First-generation NSCs were treated with eB1-Fc, and second-generation NSCs were used for H3K4me3 ChIP analyses.
(G) First-generation NSCs were treated with oligomycin, and second-generation NSCs were used for H3K4me3 ChIP analyses.
(H) Graphical presentation of the in vivo experimental design. eB1-Fc was injected in the ventricle of E13.5 embryos, and NSCs were collected at P0 and cultured
as neurospheres.
(I) SFU was quantified for NSCs isolated from different P0 pups (n = 5 for control and eB1-Fc-treated conditions), at two different passages.
(J) P0 NSCs isolated from pups injected with IgG or eB1-Fc were analyzed by western blot (n = 5 embryos for each condition).
(legend continued on next page)
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decrease in H3K4me3 levels (Figure 3C). Last, H3K4me3 levels
were increased in Efnb1/Efnb2 dKO embryos (Figure S3B).
Together, these data indicate that activation of Eph signaling
modifies H3K4me3 levels via modulation of DHFR and the 1C
folate pathway.
Next, we askedwhether decrease in H3K4me3 levels detected
bywestern-blot analyses reflected changes inH3K4me3 levels at
specific promoters. Using available H3K4me3 chromatin immu-
noprecipitation-sequencing (ChIP-seq) data (Albert et al., 2017;
Wu et al., 2011), we designed RT-PCR primers for promoters of
progenitor-specific genes (Sox2 and Nes [Nestin]), genes ex-
pressed in lineage committed cells (Olig2, GFAP, Dcx), and a
control gene (Ccdc103), and performed H3K4me3 chromatin
immunoprecipitation (ChIP) experiments on NSCs. While eB1-
Fc treatment led to decreased H3K4me3 levels on progenitor-
specific genes, other genes exhibited no change or increased
levels of H3K4me3 (Figures 3D–3I). Importantly, MTX treatment
also led to H3K4me3 decrease at promoters of progenitor-spe-
cific genes (Figure S3C).
Because H3K4me3 is generally enriched at promoters of
actively transcribed genes, it was important to show that the
changes in H3K4me3 observed following eB1-Fc treatment
were not a consequence of differentiation. To do this, we per-
turbed mitochondrial electron transport chain using oligomycin,
an ATP synthase inhibitor (Liu and Schubert, 2009), which pro-
motes differentiation. Indeed, oligomycin treatment decreased
the NSC capacity to form secondary spheres (Figure S3D),
decreased the number of SOX2+ cells (Figures S3E and S3F),
and increased the differentiated fraction (Figures S3G and
S3H). Importantly, while oligomycin treatment impaired NSC
self-renewal in a manner similar to eB1-Fc treatment, it did not
lead to a change in global H3K4me3 levels (Figure 3J), nor did
it lead to a decrease in H3K4me3 levels at promoters of progen-
itor-specific genes. However, both oligomycin and eB1-Fc treat-
ments led to an increase in H3K4me3 at the DCX promoter with
the P1 primer pair (Figures 3H and 3K), suggesting that this
modification could be secondary to the implementation of a dif-
ferentiation program.
Altogether, these results indicate that DHFR inhibition down-
stream of Eph signaling leads to decreased H3K4me3, which
differentially affects promoters.
Long-Term Inheritance of the Epigenetic Changes and
Pro-differentiation Program Induced by Eph Signaling
Changes in histone methylation are generally associated with
long-term cell fate decisions (Greer and Shi, 2012). To inves-
tigate the stability of the changes observed upon eB1-Fc
treatment, we designed an in vitro protocol to generate sec-
ond-generation NSCs, which are not themselves exposed to
treatment (Figure 4A) and have a normal level of DHFR activity
(Figure 4B). Similar to first-generation NSCs, the self-renewing
capacity of the second-generation NSCs was lower following(K) Quantification of SOX2 relative levels (SOX2 versus tubulin ratio) from (J).
(L) Quantification of H3K4me3 relative levels (H3K4me3 versus H3 ratio) from (J)
Experiments were performed on three different cultures (n = 3–5 replicates). W.B.,
using paired t test (B and D), Mann-Whitney test (B, C, D, E, I, K, and L), and one-w
Data are reported as mean ± SEM (*p < 0.05; **p < 0.01).
2870 Cell Reports 23, 2864–2873, June 5, 2018treatment with eB1-Fc (Figure 4C) and the number of SOX2+
cells was reduced (Figure 4D). Similar results were obtained
with second-generation NSCs following MTX treatment (Fig-
ure S4A). These changes were not a consequence of the first-
generation decrease in SOX2+ cells since oligomycin treatment
had no detectable effect on the second-generation self-renew-
ing potential or number of SOX2+ cells (Figures 4C, 4D, and
S4B). FACS and IF analyses show that the decrease in the pro-
genitor fraction in the second generation upon eB1-Fc treatment
correlates with an increase in the fraction of second-generation
differentiated cells (Figures 4E, S4C, and S4E). No change in
the differentiated fraction was observed in second-generation
NSCs following oligomycin treatment (Figures 4E, S4D, and
S4F). Last, FNA supplementation of first-generation NSCs
rescued the phenotypes observed following eB1-Fc treatment
at day 14 (Figures 4C–4E). Next, to address whether the loss of
self-renewing capacity correlated with the inheritance of epige-
netic modifications, we analyzed H3K4me3 levels at the pro-
moters of progenitor and differentiation-specific genes in sec-
ond-generation NSCs. Except for one primer pair (P2 for the
Sox2 gene), the profile of H3K4me3 in second-generation
NSCs was similar to that observed in first-generation NSCs
following treatment with eB1-Fc (Figure 4F), indicating that the
changes in this epigenetic mark are transmitted to the progeny.
Oligomycin treatment had no effect on the level of H3K4me3 at
either tested promoters in second-generation NSCs (Figure 4G).
To confirm the long-term inheritance of epigenetic changes and
pro-differentiation program in vivo, injection of eB1-Fc was per-
formed at E13.5 and NSCs were collected at postnatal day 0 (P0)
and used either for sphere-forming analyses or for western-blot
analyses (Figure 4H). At two distinct passages, NSCs collected
from pups that had been injected with eB1-Fc exhibited a
reduced ability to form spheres in culture (Figure 4I) and reduced
SOX2 and H3K4me3 levels (Figures 4J–4L).
Taken together, these results indicate that Eph-B forward
signaling triggers long-term epigenetic changes correlating
with differentiation and suppression of self-renewal.
DISCUSSION
Cell differentiation requires coordinated genetic and metabolic
programs to allow for a more efficient energy production match-
ing the evolving metabolic demands of a specialized progeny.
While cross talks between metabolic and signaling pathways
have been well documented in the control of cell growth and pro-
liferation (Folmes et al., 2012a; Vander Heiden et al., 2011), how
metabolic pathways are regulated to maintain SCs or drive them
along specific lineages remain to be defined. Here, we show that
local cell-to-cell communication regulates 1C metabolism in
NSCs with consequences on self-renewal and differentiation.
One key co-factor of the 1C pathway is folate (also known as
vitamin B9), which, in animals, is provided through nutrition. It.
western blot; SSA, secondary sphere assay. Statistical analysis was performed
ay ANOVA test followed by Holm-Sidak multiple-comparison test (C, D, and E).
has been known for many years that folate deficiency during
pregnancy yields a higher risk of neural tube defect (Schorah
et al., 1980). More recently, a human syndrome characterized
by low folate levels in the cerebrospinal fluid (cerebral folate defi-
ciency) has been shown to correlate with mutations in genes
coding for enzymes or transporters of the 1C folate pathway
(Serrano et al., 2012). For instance, mutations inDHFR cause se-
vere neurological disorders including microcephaly, the latter
being consistent with an alteration in the production or survival
of neurons during fetal life (Banka et al., 2011; Cario et al., 2011).
Within the developing neocortex, NSCs are exposed to folate
through the cerebrospinal fluid and they express Eph receptors
and ephrins, including ephrin-B1 (Arvanitis et al., 2013). We pro-
pose that variations in ephrin expression, either as a function of
position or time, or upon cell differentiation (Arvanitis et al.,
2010), modulate DHFR expression in neighboring cells, thus
modifying epigenetic marks and contributing to prime NSCs for
differentiation. One difference between our in vitro and in vivo an-
alyses are the kinetics of differentiation; indeed, increased differ-
entiation was observed after 3 days of eB1-Fc treatment in vivo
but only 7 days in vitro. This could be due to the fact that the
in vitro analyses were performed in culture conditions that favor
self-renewal, while NSCs in the developing neocortex are
exposed to differentiative cues. Interestingly, our data show
that, oncemodified, the epigenetic landscape and the pro-differ-
entiative state of NSCs ismaintained in the long term, suggesting
that signaling events occurring early in the neocortex develop-
mental sequence have consequences at later time.
The 1C pathway has two major branches, the methionine and
DNA synthesis branches that act on methylation reaction and
cellular proliferation, respectively. Since no change in apoptosis
or cellular proliferation was observed, our results indicate that
activation of Eph signaling mainly perturbs the methionine
branch of the 1C pathway in NSCs. Indeed, in vitro stimulation
of Eph signaling led to a decrease in H3K4me3 levels, while other
histone-3methylationwere not strongly affected. Such a specific
decrease in H3K4me3 levels has been observed following
perturbation of the methionine cycle via methionine or threonine
deprivation (Mentch et al., 2015; Shiraki et al., 2014; Shyh-Chang
et al., 2013). Thus, it was proposed that maintenance of the
H3K4me3 levels in SCs requires high SAM levels, while the
threshold required for other histone methylation appears to be
lower. Interestingly, we show that decrease of H3K4me3was de-
tected at promoters of progenitor-related genes and not differ-
entiation-related genes. While we have not investigated the
causes for this specificity, metabolites can act as cofactors
for epigenetic modifications and selectivity may result from
gene-specific recruitment of histone methyltransferases or his-
tone demethylases that have differential response to metabolite
fluctuations (van der Knaap and Verrijzer, 2016).
It has been shown in mouse embryonic SCs (mESCs) that the
global decrease in H3K4me3 levels following threonine depriva-
tion and perturbation of the methionine cycle correlated with a
decreased expression of pluripotency genes, including SOX2
(Shyh-Chang et al., 2013). In fact, modulation of the methionine
cycle has been shown to impact SC maintenance versus differ-
entiation both in mESC and in human induced pluripotent SCs
(hiPSs) (Shiraki et al., 2014; Shyh-Chang et al., 2013). Our resultsindicate that maintenance of somatic SC fate also requires high
activity of the methionine branch of 1C metabolism. In conclu-
sion, our data highlight a molecular cascade stretching from
the cell surface to the transcriptional program and epigenetic
landscape of NSCs. They further suggest that stifling of 1Cmeta-
bolism could be an integral part of differentiation programs.
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Antibodies
Mouse monoclonal anti-DHFR (used at 1/500) R&D systems Cat#MAB7934
Rabbit polyclonal anti-H3K27me3 (used at 1/1000) Millipore Cat#07-449, RRID:AB_310624
Rabbit monoclonal anti-H3K4me2 (used at 1/2000) Abcam Cat#ab32356, RRID:AB_732924
Mouse monoclonal anti-H3K9me2 (used at 1/2000) Abcam Cat#ab1220, RRID:AB_449854
Rabbit polyclonal anti-H3K4me1 (used at 1/4000) Abcam Cat#ab8895, RRID:AB_306847
Rabbit polyclonal anti-H3K4me3 (used at 1/1000) Abcam Cat#ab8580, RRID:AB_306649
Rabbit polyclonal anti-Sox2 (used at 1/300) GeneTex Cat#GTX101507, RRID:AB_2038021
Rabbit monoclonal anti-Cleaved caspase 3 (used at 1/500) Cell Signaling
Technology
Cat#9664, RRID:AB_2070042
Rabbit polyclonal anti Eph receptor B1 + Eph receptor B2
(phosphor Y594) (used at 1/250)
Abcam Cat#ab61791, RRID:AB_2099832
Mouse monoclonal anti-Oligodendrocyte marker O4
(used at 1/500)
R&D systems Cat#NL1326V, RRID:AB_1856848
Mouse monoclonal anti-Nestin (used at 1/300) DSHB Cat#Rat-401, RRID:AB_2235915
Mouse monoclonal anti-Tubulin (used at 1/5000) Sigma-Aldrich Cat#T9026, RRID:AB_477593
Mouse monoclonal anti-Histone H3 phospho (Ser10) Millipore Cat#17-685, RRID:AB_1977260
Rabbit polyclonal anti-Glial Fibrillary Acidic Protein Dako Cat#Z0334, RRID:AB_10013382
Rabbit polyclonal anti-AKT (phosphor Ser473) (used at 1/1000) Cell Signaling
Technology
Cat#9271, RRID:AB_329825
Rabbit polyclonal anti-AKT (used at 1/1000) Cell Signaling
Technology
Cat#9272, RRID:AB_329827
Rabbit polyclonal Anti- Ephrin B1/2/3 (C-18) (used at 1/1000) Santa Cruz
Biotechnology
Cat#sc-910, RRID:AB_631413
Mouse monoclonal SATB2 antibody (used at 1/40) Abcam Cat#ab51502, RRID:AB_882455
Rabbit polyclonal TBR1 antibody (used at 1/100) Abcam Cat#ab31940, RRID:AB_2200219
Rabbit polyclonal YY1 antibody (used at 1/1000) Novus Cat#NBP1-46218, RRID:AB_10009450
Rabbit polyclonal E2F1 antibody (western blot) (used at 1/1000) Abcam Cat#ab179445
Rabbit polyclonal E2F1 antibody (ChiP) Cell Signaling
Technology
Cat#3742, RRID:AB_2096936
Donkey Anti-Rabbit IgG(H+L) Antibody, CF488A Conjugated Biotium inc Cat#20015-1, RRID:AB_10854232)
Donkey Anti-Rabbit IgG(H+L) Antibody, CF555 Conjugated Biotium inc Cat#20038, RRID:AB_10558011
Donkey Anti-Rabbit IgG (H+L) Antibody, CF647 Conjugated Biotium inc Cat#20047, RRID:AB_10559808)
DRAQ5 (used at 1/2000) Biostatus Cat#DR50050, RRID:AB_2314341
Goat anti Human IgG (H+L) affinity purified PAb, X absorbed R&D systems Cat#G-101-C-ABS
Peroxidase-AffiniPure Donkey Anti-Mouse IgG (H+L) Jackson
ImmunoResearch
Cat#715-035-150, RRID:AB_2340770
Peroxidase-AffiniPure Donkey Anti-Rabbit IgG (H+L) Jackson
ImmunoResearch
Cat#711-035-152, RRID:AB_10015282
Chemicals, Peptides, and Recombinant Proteins
Protein A-Agarose BioVision Cat#6526
Protein G Sepharose, Fast Flow Sigma-Aldrich Cat#3296
E2F1 On-TARGETplus SmartPool siRNA Dharmacon Cat#L-003259-00-0005
YY1 On-TARGETplus SmartPool siRNA Dharmacon Cat#L-011796-00-0005
DHFRL1 cDNA clone expression plasmid, C-HA tag Sino Biological Cat#HG15114-CY
Folinic acid calcium salt hydrate (FNA) Sigma-Aldrich Cat#47612
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Recombinant mouse Ephrin-B1/Fc chimera (eB1-Fc) R&D systems Cat#473-EB
Oligomycin (used at 0,5 mM) Sigma-Aldrich Cat#O4876
Methotrexate hydrate (MTX) (used at 1mg/ml) Sigma-Aldrich Cat#M8407
Bovine Serum Albumin Fraction V - pH 7 (BSA) Euromedex Cat#04100811C
MK-2206 2HCl Selleckchem Cat#S1078
Akt inhibitor VIII (used at 5mM) Sigma-Aldrich Cat#A6730
LY294002 (used at 10mM) Sigma-Aldrich Cat#L9908
Putrescine Sigma-Aldrich Cat#P5780
B-27 supplement Invitrogen Cat#17504-044
Insulin-Transferrin-Sodium Selenite Supplement (ITSS) Sigma-Aldrich Cat#I1844-1VL
Fibroblast Growth Factor-basic (FGF) Sigma-Aldrich Cat#F029
Epidermal Growth Factor (EGF) Sigma-Alrich Cat#E9644
Accutase solution Sigma-Aldrich Cat#A6964
RNase A, DNase and protease-free ThermoFisher Cat#EN0531
Yeast tRNA ThermoFisher Cat#AM7119
Proteinase K Sigma-Aldrich Cat#P6556
DMEM/F12 Invitrogen Cat#1130-032
RQ1 RNase-Free DNase Promega Cat#M6101
DL-Dithiothreitol (DTT) Promega Cat#P1171
RNasin Roche Cat#N2511
16% Paraformaldehyde AQ Solution (PFA) Fisher scientific Cat#15710
Vetflurane Vibrac Cat#Vnr137317
2-Mercaptoethanol Sigma-Aldrich Cat#63689
Glycerol Sigma-Aldrich Cat#G9012
Roti-Phenol Carl ROTH Cat#0038.2
Lithium Chloride (LiCl) Sigma-Aldrich Cat#L4408
NONIDET P-40 Sigma-Aldrich Cat#N6507
Glycine Sigma-Aldrich Cat#G7126
Hydrochloric acid (HCl) Sigma-Aldrich Cat#30721
Ethanol VWR chemicals Cat#20821.330
Triton X-100 Sigma-Aldrich Cat#T9284
Sodium dodecyl sulfate (SDS) Euromedex Cat#EU0660
N-Lauroylsarcosine Sigma-Aldrich Cat#L5777
Sodium Chloride (Nacl) Euromedex Cat#1112-A
Tris Base Euromedex Cat#26-128-3094-B
Mowiol Sigma-Aldrich Cat#81381
Ethylene-bis(oxyethylenenitrilo) tetraacetic acid (EGTA) Sigma-Aldrich Cat#E4378
Ethylenediaminetetraacetic acid (EDTA) Euromedex Cat#EU0007
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Cat#D8418
Tris HCl Euromedex Cat#EU0011
Potasium Chloride (KCl) Euromedex Cat#P017-A
Pipes Sigma-Aldrich Cat#P6757
Dulbecco’s Phosphate Buffered Saline (PBS) Sigma-Aldrich Cat#D1408
D+ Glucose anhydrous Euromedex Cat#UG3050
Fetal Bovine Serum (FBS) ThermoFisher Cat#10500064
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich Cat#78830
Sodium Bicarbonate (NaHCO3) Sigma-Aldrich Cat#71631
Sodium orthovanadate (Na3VO4) Sigma-Aldrich Cat#S6508
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Sodium deoxycholate (C24H39NaO4) Sigma-Aldrich Cat#D6750
Bromophenol Blue Sigma-Aldrich Cat#B0126
Glycogen ThermoFisher Cat#R0561
Critical Commercial Assays
Dihydrofolate Reductase Assay Kit Sigma-Aldrich Cat#CS0340
Superscript III Reverse Transcriptase Invitrogen Cat#18080093
Lipofectamine RNAiMAX ThermoFisher Cat#13778075
Nucleofector kits for Mouse Neural SCs Lonza Cat#BPG-1004
Deposited Data
RNA-microarray of non and eB1-FC stimulated NPCs This paper GEO: GSE104068
Experimental Models: Cell Lines
Primary mouse NSC STAR Methods NA
Experimental Models: Organisms/Strains
Wild type mice In house breeding NA
Efnb1/; Efnb2lox/lox; nestin-Cre In house breeding NA
Oligonucleotides
Primers for qRT-PCR: listed in Table S1 This paper See Table S1
Software and Algorithms
ImageJ NIH https://imagej.nih.gov/ij/
FlowJo FLOWJO LLC https://www.flowjo.com/
GraphPad Prism 5.0 GraphPad Sofware https://www.graphpad.com/scientific-
software/prism/
Photoshop Adobe Systems https://www.adobe.com/
DAVID Bioinformatics Resources 6.8 Leidos Biomedical
Research
https://david.ncifcrf.gov/
BIO-RAD CFX Manager BIO-RAD http://www.bio-rad.com
LAS X Leica Microsystems https://www.leica-microsystems.com/
CellQuest Pro BD Bioscience http://www.bdbiosciences.com/us/instruments/
clinical/cell-analyzers/bd-facscalibur/software/
bd-facstation-v61x-for-mac-os-x/p/643436
Other
DNase-free water Sigma-Aldrich Cat#W4502
SsoFast EvaGreen Supermix BIO-RAD Cat# 1725204
Amersham Hyperfilm ECL GE Healthcare Limited Cat#28906836
Superfrost glass slides ThermoFisher Cat#LR90SF03
Tween 20 Euromedex Cat#2001-A
Glass beads, acid-washed Sigma-Aldrich Cat#G8772
Complete, Mini, EDTA-free Protease Inhibitor Cocktail Roche Cat#11836170001
TRI Reagent MRC Cat#TR118
Acrylamid/Bisacrylamide 29/1 Euromedex Cat#EU0063-C
Clarity Western ECL Substrate BIO-RAD Cat#170-5060
Lumi-Lightplus Western Blotting Substrate Roche Cat#12015196001
Amersham Protran western blotting membranes,
nitrocellulose
GE Healthcare Limited Cat#GE10600002
HEPES Buffer Sigma-Aldrich Cat#H0887
CELLOMETERTM mini Nexcelom Cat#1001201
Cellometer Counting Chambers Nexcelom Cat#CHT4-PD100-002
Diagenode Biorupter Sonicator Diagenode Cat#B01020001
Mini-PROTEAN Tetra Vertical Electrophoresis Cell BIO-RAD Cat#1658001
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Mini Trans-Blot Electrophoretic Transfer Cell BIO-RAD Cat#1703930
FACSCalibur cytometer Becton Dickinson Cat#342975
JENWAY 7200 Scanning Spectrophotometer JENWAY Cat#720 501
Leica VT1000 S Microtome Leica Biosystems Cat#VT1000 S
CFX96 Real-Time PCR Detection System BIO-RAD Cat#185-5096CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources reagents should be directed to and will be fulfilled by the Lead Contact, Alice Davy
(alice.davy@univ-tlse3.fr).
EXPERIMENTAL MODEL AND PERMISSIONS
Animals
Wild-type mice kept in a 129S4/C57Bl6J mixed background were bred in the animal facility. Efnb1loxlox, Efnb2loxlox in a 129S4/
C57Bl6J mixed background and Nestin-Cre C57Bl6J background mouse lines have been described previously (Davy et al., 2004;
Grunwald et al., 2004; Tronche et al., 1999). To generate compound mutants, Efnb1loxlox; Efnb2loxlox females were bred with
Nestin-Cre; Efnb1Ylox; Efnb2loxloxmales. Neonates and E13.5 embryos were individually genotyped by PCR. The gender of neonates
and embryos was not tested since there is currently no evidence for gender bias in neocortical NSC development. Animal procedures
were pre-approved by the national Animal Care and Ethics Committee (APAFIS#1289-2015110609133558 v5) following Directive
2010/63/EU.
Culture of NPCs and Maintenance
Cultures of primary NPCs were obtained as described previously (Chojnacki and Weiss, 2008). Briefly, embryonic day 14.5 (E14.5)
cortices were dissected mechanically in phosphate buffered saline solution (PBS) (Cat#D1408, Sigma). The single-cell suspension
was collected, rinsed with DMEM/F12 (Cat#1130-032, Invitrogen), and cultured with growing medium (DMEM/F12 medium contain-
ing 0.6% glucose (Cat#UG3050, Euromedex), 5 mM HEPES (Cat#H3375, Sigma), 1 mM putrescine (Cat#P5780, Sigma), 5 ng/ml
basic fibroblast growth factor 2 [FGF-2] (Cat#F029, Sigma), 20 ng/ml epidermal growth factor [EGF] (Cat#E9644, Sigma),
10 ng/ml insulin-transferrin-sodium selenite supplement (Cat#I1844-1VL, Sigma) and 2% B27 supplement (Cat#17504-044,Invitro-
gen)) in a 5% CO2 incubator at 37
C. Several different primary cultures were obtained and kept in culture for no more than 5 pas-
sages. Fresh medium was added every 2-3 days to the culture and passage was realized once a week using Accutase
(Cat#A6964, Sigma).
METHODS DETAILS
Stimulation of Eph Forward Signaling in NSC
Prior to stimulation, neurospheres were dissociated with Accutase (Cat#A6964, Sigma), and aliquots of 105 cells were placed in
growing medium then stimulated with 1 mg/ml eB1-Fc (Cat#473-EB, R&S Systems) preclustered with 0.1 mg/ml anti-human IgG
(Cat#G-101-C-ABS, R&D Systems). Total RNA was isolated 6h, 72 hr post-stimulation and processed for qRT-PCR. Alternatively,
cells were stimulated for 30min, 6h, 24h and 72 hr and lysed in protein lysis buffer for western blot analysis.
NSC Transfection
Prior to stimulation and transfection, neurospheres were dissociated with Accutase (Cat#A6964, Sigma), and aliquots of 106 cells
were placed in growing medium then stimulated with 1 mg/ml eB1-Fc (Cat#473-EB, R&S Systems) preclustered with 0.1 mg/ml
anti-human IgG (Cat#G-101-C-ABS, R&D Systems). siRNA E2F1 (Cat#L-003259-00-0005) and siRNA YY1 (Cat#L-011796-00-
0005) were complexed with lipofectamine RNAiMAX (Cat#13778075) and added to the culture media at the same time as eB1-Fc
stimulation and 24h post-stimulation. For DHFRL1 (Cat#HG15114-CY) expression, NSC were dissociated and 106 cells were
cultured for 48h. NSC were then electroporated using Amaxa nucelofection reagent (Cat#BPG-1004) and analyzed after 72 hr by
western blot.
Microarray Analysis
MouseWG-6_V2_0_R3_11278593_A.txtwas obtained from Illumina and used to extract Illumina identifiers (column: Array_Address_Id)
and probe sequences (column: Probe_Sequence), which were converted to nuIDs using lumi:seq2id() (Du et al., 2007, 2008). The limu:
lumiMouseAllACCNUMR object was used tomap nuIDs to RefSeq accessions. By connecting through the nuID, wewere then able toCell Reports 23, 2864–2873.e1–e7, June 5, 2018 e4
assign RefSeq accessions and relevant gene identity information to each probe on the microarray. The readIDAT_enc() function from
illumiaio (Smith et al., 2013) was used in order to read theGrn.idat binary files and obtain the TrimmedMeanBinData, whichwas assem-
bled into a matrix for downstream limma analyses (Ritchie et al., 2015). Quantile normalization was applied with limma:normalize
BetweenArrays and limma was used to optain log2 Fold Change and p values for each contrast (lmFit, contrasts.fit and eBayes). To
identify genes differentially expressed upon forward signaling activation, the forward-2hour, forward-6hour and control-6hour
data were contrasted against the control-2hour time (n = 3 for each group). The differential expression between control-6hour and
control-2hour was used to evaluate the time-dependent changes in gene expression, independently of treatment. p values were
adjusted via limma:topTable (Benjamini Hochberg method) and all results were assembled into data.frame for further queries by biol-
ogists using a spreadsheet program.
Cell Proliferation Assay
Neurospheres were dissociated with Accutase (Cat#A6964, Sigma), and cells were seeded in triplicate in a 6-well plate at 104 cell/ml
density. Cell number was measured using Cellometer (Cat#1001201, Nexcelom) according to the manufacturer’s instructions.
Sphere Forming Assays
Neurospheres were dissociated with Accutase (Cat#A6964, Sigma), and about hundred cells were seeded in a 96-well plate, and the
total number of spheres was counted 2 weeks after incubation. eB1-Fc (Cat#473-EB, R&S Systems), Methotrexate (Cat#M8407,
Sigma) and Oligomycin (Cat#O4876, Sigma) were added to the assay culture medium upon seeding to a final concentration of
1 mg/ml, 2 mM and 0.1 mg/ml respectively. Sphere-Forming Unit (SFU) was calculated: SFU = (number of spheres counted / number
of input cells) * 100.
Quantitative PCR
RNAwas extracted from cell pellets using TRIreagent (Cat#TR118,MRC) according to themanufacturer’s instructions. 1 mg RNAwas
used for reverse transcription. Genomic DNA was degraded with 1 ml DNase (Cat#M6101, Promega) for 20 min at 37C in 20 ml
RNase/DNase-free water (Cat#W4502, Bio-RAD), and the reaction was stopped by adding 1 ml stop solution under heat inactivation
at 65C for 10 min. 2 ml dNTPs (10 mM; Promega) and 2 ml oligodTs (100 mM, idtDNA) were added for 5 min at 65C, then 8 ml of
5 3 buffer, 2 ml RNasin (Cat#N2511, Roche), and 4 ml of 100 mM DTT (Cat#P1171, Promega) were added for 2 min at 42C. The
mix was divided into equal volumes in a reverse-transcriptase–negative control tube with addition of 1 ml water and in a reverse-tran-
scriptase–positive tube with 1 ml superscript enzyme and placed at 42C for 1 hr. The reaction was stopped at 70C for 15 min, and
cDNAs were diluted (10-, 100-, and 1,000-fold) and processed for quantitative PCR in triplicate for each dilution. 10 ml diluted cDNA
wasmixed with 10 ml premix Evagreen (Cat# 1725204, Bio-RAD) containing 1mMof each primer, and the PCR programwas run for 40
cycles on a CFX96 BioRad Realtime system (Cat#185-5096, Bio-RAD). mRNA relative expression levels were calculated using the
2-DDCts method. Primers are listed in Table S1.
In Utero Injections
Timed-pregnant mice were anesthetized using Vetflurane (Cat#Vnr137317, Vibrac) and uterine horns were exposed. DMSO, 1 mg/ml
MTX (Cat#M8407, Sigma), 1 mg/ml pre-clustered human IgG-Fc (Cat#G-101-C-ABS, R&D Systems) or 1mg/ml pre-clustered eB1-Fc
(Cat#473-EB, R&S Systems) were injected in the lateral ventricle of E13.5 embryos neocortex using pulled micropipettes. Body wall
cavity and skin were sutured and embryos were allowed to develop normally for 72 hr or until birth. Embryonic brains were collected
at E16.5, fixedwith 4%paraformaldehyde (Cat#15710, Fisher scientific) overnight at 4C. Vibratome sections (50 mm) (Cat#VT1000 S,
Leica Biosystems) were processed for IF staining as described below. Alternatively, brains were collected at P0, the neocortex was
dissected and cells were dissociatedwith Accutase. Dissociated cells were plated for 72 hr in growth factor containingmedium and
used either for western blot analyses or for secondary sphere assay.
IF and Flow Cytometry
For IF, cells were grown and treated as described earlier on. Neurospheres were collected and fixed at room temperature with 4%
paraformaldehyde (Cat#15710, Fisher Scientific) for 30 min, then permeabilized and blocked with PBTA solution (0.5% BSA
(Cat#04100811C, Euromedex), 0.5% FBS (Cat#10500064, ThermoFisher), and 0.1% Triton X-100 (Cat#T9284, Sigma) in PBS
(Cat#D1408, Sigma) for 30 min. Primary and secondary antibodies diluted in PBTA were incubated overnight at 4C and 2h at
room temperature, respectively. Neurosphereswere collectedwith centrifugation at 1,200 rpm for 10min at each step. Neurospheres
were finally mounted on glass slides (Superfrost) (Cat#LR90SF03, ThermoFisher) with Coverslips using mounting medium (4.8%
wt/vol Mowiol (Cat#81381, Sigma) and 12% wt/vol glycerol (Cat#G9012, Sigma) in 50 mM Tris pH 8.5 (Cat#26-128-3094-B,
Euromedex)).
Cortices were permeabilized and blocked with PBTA2 solution (2% BSA, 2% FBS, 1% Tween20 (Cat#2001-A, Euromedex) for 2h
at room temperature. Primary antibodies diluted in PBTA2 and secondary antibodies diluted in PBSwere incubated about 36h at 4C
and 1.5h at room temperature respectively. Labeled sections were finally mounted on glass slides (Superfrost) with Coverslips using
mounting medium (4.8% wt/vol Mowiol and 12% wt/vol glycerol in 50 mM Tris, pH 8.5).e5 Cell Reports 23, 2864–2873.e1–e7, June 5, 2018
Microscope acquisitions were performed on either an SP5 DM600B confocal microscope (40 3 /1.3 APO; 20 3 /0.7 APO, PMT;
Leica Biosystems) or an SP8 droit (40x, TCS; Leica Biosystems). Observation was performed using Type-F mineral oil (1153859; Le-
ica Biosystems). Cell counting and pixel quantification were performed with the use of ImageJ software.
For fluorescence-activated cell sorter (FACS) analysis, neurospheres were dissociated with Accutase (Cat#A6964, Sigma) and
approximately 106 cells in 1.2ml ice-cold PBSwere fixed in 4%PFA. The cell suspensionwas incubated in 200ml PBTA first with either
anti-Tuj1 and anti-SOX2 antibodies or anti-GFAP and anti-O4 antibodies and then with a secondary antibody coupled to AlexaFluor
488 and 647 for overnight at 4C and 2h at room temperature respectively. Cells were resuspended in 500ml PBS and acquired with a
FACSCalibur cytometer (Cat#342975, Becton Dickinson). To set the threshold for specific positive fluorescence intensity signal, we
use control samples with cells incubated with secondary antibodies alone.
Protein Extraction and Western Blot
For protein extraction, Neurospheres were pelleted by centrifugation at 1,500 rpm for 10 min and washed twice with an ice-cold PBS
(Cat#D1408, Sigma) solution. Whole cell extracts were obtained by re-suspending cell pellets in the following ice-cold lysis buffer
(150 mM NaCl (Cat#1112-A, Euromedex), 50 mM Tris-HCl pH 7.4 (Cat#EU0011, Euromedex), 0.5 mM EDTA (Cat#EU0007, Eurome-
dex), 2 mM Na3VO4(Cat#S6508, Sigma), 1% Nonidet P-40 (NP-40) (Cat#N6507, Sigma), 0.5 mM EGTA (Cat#E4378, Sigma) and
0.1 mM PMSF (Cat#78830, Sigma)) supplemented by protease inhibitors (Cat#11836170001, Roche) for 1h on ice. Protein lysates
were then vortexed, sonicated with Biorupter Sonicator for 10 cycles (Cat#B01020001, Diagenode), and centrifuged at
13,000 rpm for 10 min. Cleared lysates were either used for western blot analyses. Samples were denatured by boiling in loading
buffer (43 100 mM Tris-HCL, pH 6.8, 8% SDS (Cat#EU0660, Euromedex), 40% glycerol (Cat#G9012, Sigma), 4% b-mercaptoetha-
nol (Cat#63689, Sigma), and bromophenol blue (Cat#B0126, Sigma)) before loading and electrophoresis on an 8 or 16% SDS-PAGE
gel. Proteins were transferred onto a nitrocellulose membrane (Cat#GE10600002,GEHealthcare), which was blocked for 30min and
incubated with primary antibody in 5% nonfat dry milk in TBS-T (20 mM Tris base (Cat#26-128-3094-B, Euromedex), 150 mM NaCl,
and 0.05% Tween 20 (Cat#2001-A, Euromedex) adjusted to pH 7.6 with 1 M HCl (Cat#30721, Sigma)) overnight at 4C. Milk was
replaced with 5% BSA (Cat#04100811C, Euromedex) for detection of phosphorylated epitopes. Western blots presented are repre-
sentative of at least three independent experiments.
DHFR Catalytic Assay
DHFR activity, measured as folate reductase, was determined by the dihydrofolate reductase assay kit according to the manufac-
turer’s instructions. Briefly, cells were pelleted by centrifugation at 1,500 rpm for 10 min and washed twice with an ice-cold PBS so-
lution (Cat#D1408, Sigma). Cell pellets were resuspended in 300ml assay buffer supplemented with protease inhibitors
(Cat#11836170001, Roche) and lysed mechanically using glass beads (Cat#G8772, Sigma). Lysates were precleared by centrifuga-
tion at 13,000 rpm for 10 min. The supernatant was used immediately for enzyme assay after the determination of protein
concentration.
Chromatin Immunoprecipitation Protocol
NPCs were treated as described above and cultured for 72 hr. Cells were fixed with 1% formaldehyde (Cat#15710, Fisher Scientific)
for 15 min at room temperature, with occasional swirling. Glycine (Cat#G7126, Sigma) was added to a final concentration of 0.125 M
and the incubation was continued for an additional 5 min. Cells were collected and washed with ice-cold PBS (Cat#D1408, Sigma)
three times and resuspended in cell lysis buffer (5 mMPipes [pH 8] (Cat#P6757, Sigma), 85mMKCl (Cat#P017-A, Euromedex), 0.5%
NP-40 (Cat#N6507, Sigma), Protease inhibitors (Cat#11836170001, Roche). Cells were centrifuged at 4000 rpm for 10 min at 4C.
Pellets were then resuspended in Nuclei lysis buffer (50 mM Tris-HCl [pH 8] (Cat#EU0011, Euromedex), 10 mM EDTA, 1% SDS).
The cells were disrupted by sonication (30 cycles, 30 s on, 60 s off) with Biorupter Sonicator (Cat#B01020001, Diagenode). The
chromatin solution was clarified by centrifugation at 15,000 g at 4C for 10 min. The average DNA fragment size was 250 pb. The
chromatin solution was diluted with IP dilution buffer (16.7 mM Tris-HCl [pH 8], 1.2 mM EDTA (Cat#EU0007, Euromedex), 1.1 mM
Triton X-100 (Cat#T9284, Sigma), 0.01% SDS (Cat#EU0660, Euromedex) and 167 mM NaCl (Cat#1112-A, Euromedex) and pre-
cleared with pre-blocked beads (protein G Sepharose (Cat#3296, Sigma)/protein A agarose (Cat#6526, BioVision) (50/50) overnight
with PBS/0.5%BSA (Cat#04100811C, Euromedex), 10mg/ml yeast tRNA (Cat#AM7119, ThermoFisher) beads for 1h at 4C. The pre-
cleared diluted chromatin sample was incubated with either 5 mL of anti-E2F1 (Cat#3742) or 3 mg of anti-H3K4me3 (Cat#ab8580,
Abcam) overnight at 4C. Preblocked beads were added for an additional 4h. The beads were washed twice with the dialysis buffer
(2 mM EDTA, 50 mM Tris-HCl [pH 8] and 0.2% N-lauroylsarcosine (Cat#L5777, Sigma), 4 times with wash buffer (100 mM Tris-HCl
[pH 8], 500 mM LiCl (Cat#L4408, Sigma), 1% NP-40 and 1% sodium Deoxycholate (Cat#D6750, Sigma) and twice with TE buffer
(10 mM Tris-HCl [pH 8] and 1 mM EDTA). The immunoprecipitated material was eluted from the beads by heating for 15 min at
65C in 1% SDS, 50 mM NaHCO3 (Cat#71631, Sigma). 0.2 M NaCl (Cat#1112-A, Euromedex) and 10 mg/ml RNase A (Cat#EN0531,
ThermoFisher) were added before incubating for 2h at 64C to reverse the crosslinks. Samples were then incubated with 1.5 mg/ml
Proteinase K (Cat#P6556, Sigma), 40 mM Tris-HCl [pH 8], 10 mM EDTA at 45C for 1h. The samples were then extracted with phenol
chloroform isoamyl alcohol (Cat#0038.2, Carl ROTH) followed by ethanol (Cat#20821.330, VWR chemicals) precipitation in the pres-
ence of glycogen (Cat#R0561, ThermoFisher), and resuspended in DNase-free water (Cat#W4502, Sigma). The resulting precipitated
DNA was amplified and analyzed by qRT-PCR as described above.Cell Reports 23, 2864–2873.e1–e7, June 5, 2018 e6
QUANTIFICATION AND STATISTICAL ANALYSIS
For experiments involving a single pair of conditions, statistical significance between the two sets of data were analyzed with a
paired-t test, Mann-Whitney and Wilcoxon test with Prism5 (GraphPad software). For datasets containing more than two samples,
one-way analysis of variance with either Bonferroni, Holm-Sidak’s or Fisher’s LSD multiple comparison post-test was used to deter-
mine adjusted p values. Sample sizes of sufficient power were chosen on the basis of similar published research and were confirmed
statistically by appropriate tests. Each experiment was performed at least three times, and 100–500 cells were counted for each con-
dition of each experiment. Statistically significant differences are reported at p < 0.05, p < 0.01, p < 0.001.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The accession number for the microarray data reported in this paper is GEO: GSE104068.e7 Cell Reports 23, 2864–2873.e1–e7, June 5, 2018
